Details

Autor(en) / Beteiligte

• Liautard-Haag, C.
• Durif, G.
• VanGoethem, C.
• Baux, D.
• Louis, A.
• Cayrefourcq, L.
• Lamairia, M.
• Willems, M.
• Zordan, C.
• Dorian, V.
• Rooryck, C.
• Goizet, C.
• Chaussenot, A.
• Monteil, L.
• Calvas, P.
• Miry, C.
• Favre, R.
• Le Boette, E.
• Fradin, M.
• Roux, A. F.
• Cossée, M.
• Koenig, M.
• Alix-Panabière, C.
• Guissart, C.
• Vincent, M. C.

Titel

Noninvasive prenatal diagnosis of genetic diseases induced by triplet repeat expansion by linked read haplotyping and Bayesian approach

Ist Teil von

• Scientific reports, 2022-07, Vol.12 (1), p.11423-11423, Article 11423

Ort / Verlag

London: Nature Publishing Group

Erscheinungsjahr

2022

Link zum Volltext

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• Abstract The field of noninvasive prenatal diagnosis (NIPD) has undergone significant progress over the last decade. Direct haplotyping has been successfully applied for NIPD of few single-gene disorders. However, technical issues remain for triplet-repeat expansions. The objective of this study was to develop an NIPD approach for couples at risk of transmitting dynamic mutations. This method includes targeted enrichment for linked-read libraries and targeted maternal plasma DNA sequencing. We also developed an innovative Bayesian procedure to integrate the Hoobari fetal genotyping model for inferring the fetal haplotype and the targeted gene variant status. Our method of directly resolving parental haplotypes through targeted linked-read sequencing was smoothly performed using blood samples from families with Huntington’s disease or myotonic dystrophy type 1. The Bayesian analysis of transmission of parental haplotypes allowed defining the genotype of five fetuses. The predicted variant status of four of these fetuses was in agreement with the invasive prenatal diagnosis findings. Conversely, no conclusive result was obtained for the NIPD of fragile X syndrome. Although improvements should be made to achieve clinically acceptable accuracy, our study shows that linked-read sequencing and parental haplotype phasing can be successfully used for NIPD of triplet-repeat expansion diseases. Trial registration: NCT04698551_date of first registration: 07/01/2021.